Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 7/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 5/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30413710 | 0.84 | NPC1 (0.46) | NPC1RAB9AKDM4EL3MBTL1FAAH | |
| SCHEMBL1427654 | 0.77 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL2008234 | 0.75 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL22221895 | 0.75 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3331943 | 0.75 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1427656 | 0.75 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL316306 | 0.75 | KDM4E (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL2414410 | 0.75 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL7537268 | 0.75 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL10278988 | 0.75 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-06-17 | — | — | US | claimed |
| CN-113768935-B | Preventive and/or therapeutic agent for immune disease | 大鹏药品工业株式会社 | 2024-10-01 | — | — | CN | disclosed |
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024126773-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| EP-4242199-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS XII | BASF SE (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3185330-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-08-16 | — | — | EP | disclosed |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| US-11639337-B2 | Bicyclic heteroaryl derivatives and preparation and uses thereof | XWPharma Ltd. (KY) | 2023-05-02 | — | — | US | disclosed |
| US-11639337-B2 | Bicyclic heteroaryl derivatives and preparation and uses thereof | XWPharma Ltd. (KY) | 2023-05-02 | — | — | US | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-4748172-A | 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1988-05-31 | — | — | US | disclosed |
| US-4692443-A | 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0138552-A2 | Improvements on or relating to 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | NPC1 3623/4885RAB9A 515/4885SMN1; SMN2 1160/4885 |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | NPC1 3021/4885RAB9A 2719/4885SMN1; SMN2 3570/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | NPC1 2905/4885RAB9A 1526/4885SMN1; SMN2 2663/4885 |
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, OXTR | NPC1 1254/4885RAB9A 1775/4885SMN1; SMN2 3428/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | NPC1 3657/4885RAB9A 589/4885SMN1; SMN2 1245/4885 |
| US-11639337-B2 | Bicyclic heteroaryl derivatives and preparation and uses thereof | GRIN2A, GRIN2C, GRIN3A | NPC1 559/4885RAB9A 960/4885SMN1; SMN2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.